The acquisition of Kashiv BioSciences transforms Amneal into a vertically integrated biosimilars player, combining deep R&D and manufacturing with proven commercial scale. Management attributes the strategic pivot to an 'inflection point' in the biosimilars market, driven by accelerating physician adoption and regulatory advancements lowering development costs. First-quarter performance was driven by high market demand and increased supply for key women's health and ADHD products within the Affordable ...